Evotec and Forge Therapeutics form strategic “superbug” alliance
Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. (“Forge”) to advance its novel Gram-negative antibiotic programme targeting ‘LpxC’ for the treatment of bacterial infections including those caused by drug resistant ‘superbugs’. L
LpxC has been recognised as an attractive antibacterial target for more than the past 15 years; however, a lack of suitable chemical starting points has hampered its progress. Forge has been applying its proprietary metal-binding pharmacophores (“MBP”) library and processes and has been able to identify potent drugable inhibitors of LpxC.
21 April 2017
Product Validation in Health (ProVaHealth)